ABUS : Summary for Arbutus Biopharma Corporation - Yahoo Finance

U.S. Markets closed

Arbutus Biopharma Corporation (ABUS)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.650.00 (0.00%)
At close: 4:00PM EST
People also watch
RGLSAFMDDRNAADAPARWR
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.65
Open2.60
Bid2.30 x 200
Ask5.30 x 500
Day's Range2.55 - 2.67
52 Week Range2.35 - 5.48
Volume40,990
Avg. Volume315,196
Market Cap145.33M
Beta1.94
PE Ratio (TTM)-0.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals15 days ago

    Doylestown biopharm firm granted injunction over licensing dispute

    Arbutus Biopharma Corp., a two-year-old biopharmaceutical company attempting to develop a cure for hepatitis B infections, won the latest round in its ongoing dispute over a cross licensing deal it made with a Canadian drug company. This week the Supreme Court of British Columbia granted a request by Arbutus (ABUS)— which has offices in Vancouver and Doylestown, Pennsylvania — for a pre-trial injunction preventing Acuitas from sublicensing Arbutus’ lipid nanoparticle [LNP] technology until the end of October. “We are gratified by the court’s decision to grant a pre-trial injunction against Acuitas to stop Acuitas from granting unauthorized licenses and use of our LNP technology,” said Dr. Mark J. Murray, Arbutus’ president and CEO, in a prepared statement.

  • GlobeNewswire16 days ago

    Arbutus to Participate in Upcoming Investor Conferences

    VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 09, 2017-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that the company will ...

  • Forbes17 days ago

    Mysterious $5 Billion Biotech Moderna Hit With Legal Setback Related To Key Technology

    British Columbia Supreme Court Justice Dev Dley this week granted a request from Arbutus Biopharma for a pre-trial injunction that prevents a tiny company called Acuitas from sublicensing Arbutus’ lipid nanoparticle delivery technology to Moderna until the end of October.